The U.S. Food and Drug Administration (FDA) has granted 501(k) clearance to Quantel Medical’s Optimus Fusion integrated laser platform.
Clermont-Ferrand, France-The U.S. Food and Drug Administration (FDA) has granted 501(k) clearance to Quantel Medical’s Optimus Fusion integrated laser platform.
According to the company, the Optimis Fusion system combines selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional YAG photodisruption treatments to offer ophthalmologists an armamentarium for treating both cataract and glaucoma in a combination platform.
SLT therapy works by targeting melanin-rich cells that absorb the laser energy to induce a healing response, improving the function of the trabecular meshwork. Laser energy is delivered in short, fixed pulses over a large, homogeneous spot size, resulting in no thermal damage. SLT leaves structures intact, making it a repeatable procedure.
The YAG mode delivers photodisruption for capsulotomy and peripheral iridotomy surgical procedures. The gaussian laser beam profile allows for precise laser delivery at minimum energy levels, avoiding adverse side effects such as lens pitting. Precise tissue targeting is achieved with the advanced two-point aiming beam, allowing for fast and accurate targeting of the capsule, and an adjustable anterior and posterior offset feature allows for easy focus adjustment in front of, behind, or at the point of disruption.